| Literature DB >> 23764502 |
Nancy Leymarie1, Paula J Griffin, Karen Jonscher, Daniel Kolarich, Ron Orlando, Mark McComb, Joseph Zaia, Jennifer Aguilan, William R Alley, Friederich Altmann, Lauren E Ball, Lipika Basumallick, Carthene R Bazemore-Walker, Henning Behnken, Michael A Blank, Kristy J Brown, Svenja-Catharina Bunz, Christopher W Cairo, John F Cipollo, Rambod Daneshfar, Heather Desaire, Richard R Drake, Eden P Go, Radoslav Goldman, Clemens Gruber, Adnan Halim, Yetrib Hathout, Paul J Hensbergen, David M Horn, Deanna Hurum, Wolfgang Jabs, Göran Larson, Mellisa Ly, Benjamin F Mann, Kristina Marx, Yehia Mechref, Bernd Meyer, Uwe Möginger, Christian Neusüβ, Jonas Nilsson, Milos V Novotny, Julius O Nyalwidhe, Nicolle H Packer, Petr Pompach, Bela Reiz, Anja Resemann, Jeffrey S Rohrer, Alexandra Ruthenbeck, Miloslav Sanda, Jan Mirco Schulz, Ulrike Schweiger-Hufnagel, Carina Sihlbom, Ehwang Song, Gregory O Staples, Detlev Suckau, Haixu Tang, Morten Thaysen-Andersen, Rosa I Viner, Yanming An, Leena Valmu, Yoshinao Wada, Megan Watson, Markus Windwarder, Randy Whittal, Manfred Wuhrer, Yiying Zhu, Chunxia Zou.
Abstract
One of the principal goals of glycoprotein research is to correlate glycan structure and function. Such correlation is necessary in order for one to understand the mechanisms whereby glycoprotein structure elaborates the functions of myriad proteins. The accurate comparison of glycoforms and quantification of glycosites are essential steps in this direction. Mass spectrometry has emerged as a powerful analytical technique in the field of glycoprotein characterization. Its sensitivity, high dynamic range, and mass accuracy provide both quantitative and sequence/structural information. As part of the 2012 ABRF Glycoprotein Research Group study, we explored the use of mass spectrometry and ancillary methodologies to characterize the glycoforms of two sources of human prostate specific antigen (PSA). PSA is used as a tumor marker for prostate cancer, with increasing blood levels used to distinguish between normal and cancer states. The glycans on PSA are believed to be biantennary N-linked, and it has been observed that prostate cancer tissues and cell lines contain more antennae than their benign counterparts. Thus, the ability to quantify differences in glycosylation associated with cancer has the potential to positively impact the use of PSA as a biomarker. We studied standard peptide-based proteomics/glycomics methodologies, including LC-MS/MS for peptide/glycopeptide sequencing and label-free approaches for differential quantification. We performed an interlaboratory study to determine the ability of different laboratories to correctly characterize the differences between glycoforms from two different sources using mass spectrometry methods. We used clustering analysis and ancillary statistical data treatment on the data sets submitted by participating laboratories to obtain a consensus of the glycoforms and abundances. The results demonstrate the relative strengths and weaknesses of top-down glycoproteomics, bottom-up glycoproteomics, and glycomics methods.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23764502 PMCID: PMC3790302 DOI: 10.1074/mcp.M113.030643
Source DB: PubMed Journal: Mol Cell Proteomics ISSN: 1535-9476 Impact factor: 5.911